Institutional Fund
Merck & Co., Inc.
Rahway, NJCIK 3101585 filings on record
Portfolio Value
$349.44M
Q1 2026
Holdings
14
Reported positions
New Buys
3
Opened this quarter
QoQ Change
+26.5%
from $276.28M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Moderna Inc33.6%
- Personalis Inc25.6%
- Kymera Therapeutics Inc18.4%
- Entrada Therapeutics Inc6.3%
- Eikon Therapeutics Inc5.0%
- Aktis Oncology Inc4.9%
- Other6.2%
Portfolio Holdings
14 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Moderna Inc | 2.31M | $117.26M | 33.6% | 0 | Held |
| 2 | Personalis Inc | 14.04M | $89.47M | 25.6% | 0 | Held |
| 3 | Kymera Therapeutics Inc | 772.2K | $64.31M | 18.4% | 0 | Held |
| 4 | Entrada Therapeutics Inc | 1.74M | $21.96M | 6.3% | 0 | Held |
| 5 | Eikon Therapeutics Inc | 1.67M | $17.63M | 5.0% | +1.67M | New |
| 6 | Aktis Oncology Inc | 952.8K | $17.05M | 4.9% | +952.8K | New |
| 7 | Alector Inc | 3.55M | $7.62M | 2.2% | 0 | Held |
| 8 | Sutro Biopharma Inc | 272.4K | $6.78M | 1.9% | 0 | Held |
| 9 | Evaxion Biotech A/S | 1.21M | $4.52M | 1.3% | 0 | Held |
| 10 | Viridian Therapeutics Inc | 93.4K | $1.83M | 0.5% | 0 | Held |
4 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio